On Tuesday, Jan. 10, Global Healthcare will become Reuters Health Rounds, a newsletter curated by Nancy Lapid, editor in charge of Reuters Health. Reuters Health Rounds will be sent on Tuesdays and Thursdays.
The U.S. Food and Drug Administration said on Friday it does not expect AstraZeneca's COVID-19 antibody cocktail Evusheld to provide protection against the Omicron subvariant XBB.1.5.
Pharmacies across the United States are weighing whether to sell mifepristone, a pill used in medication abortions, following the Food and Drug Administration's announcement earlier this week that they can now do so.
China is in talks with Pfizer to secure a license that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug Paxlovid in the country, sources say.
The Netherlands will require travellers from China to show proof of a recent negative COVID-19 test before they are allowed into the country, the Dutch government said on Friday.
The Omicron subvariant, XBB.1.5, is estimated to account for 27.6% of COVID-19 cases in the United States for the week ending Jan. 7, data from the Centers for Disease Control and Prevention showed on Friday.
Pfizer Inc is exploring options for some early-stage treatments for rare diseases and cancer in a bid to focus on "high-impact" medicines and vaccines, the company said on Thursday.
Germany's CureVac AG said on Friday its second-generation COVID-19 vaccine produced virus-neutralizing antibodies against the BA.1 subvariant of Omicron, based on preliminary data from an early-stage trial.
Baxter International Inc said on Friday it plans to spin off its kidney care units, becoming the latest medical device maker to slim down in the face of supply-chain challenges.
The struggles of France's health system will probably get worse before things improve, President Emmanuel Macron acknowledged on Friday, as he pledged to improve working conditions and hire more medical assistants for administrative tasks.
